A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor

Sonia K. Pollitt, Judit Pallos, Jieya Shao, Urvee A. Desai, Aye Aye K Ma, Leslie Michels Thompson, J. Lawrence Marsh, Marc I. Diamond

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

Many neurodegenerative diseases, including tauopathies, Parkinson's disease, amyotrophic lateral sclerosis, and the polyglutamine diseases, are characterized by intracellular aggregation of pathogenic proteins. It is difficult to study modifiers of this process in intact cells in a high-throughput and quantitative manner, although this could facilitate molecular insights into disease pathogenesis. Here we introduce a high-throughput assay to measure intracellular polyglutamine protein aggregation using fluorescence resonance energy transfer (FRET). We screened over 2800 biologically active small molecules for inhibitory activity and have characterized one lead compound in detail. Y-27632, an inhibitor of the Rho-associated kinase p160ROCK, diminished polyglutamine protein aggregation (EC50 ≅ 5 μM) and reduced neurodegeneration in a Drosophila model of polyglutamine disease. This establishes a novel high-throughput approach to study protein misfolding and aggregation associated with neurodegenerative diseases and implicates a signaling pathway of previously unrecognized importance in polyglutamine protein processing.

Original languageEnglish (US)
Pages (from-to)685-694
Number of pages10
JournalNeuron
Volume40
Issue number4
DOIs
StatePublished - Nov 13 2003

Fingerprint

Fluorescence Resonance Energy Transfer
rho-Associated Kinases
Proteins
Neurodegenerative Diseases
Tauopathies
Amyotrophic Lateral Sclerosis
Drosophila
Parkinson Disease
polyglutamine

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Pollitt, S. K., Pallos, J., Shao, J., Desai, U. A., Ma, A. A. K., Thompson, L. M., ... Diamond, M. I. (2003). A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor. Neuron, 40(4), 685-694. https://doi.org/10.1016/S0896-6273(03)00697-4

A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor. / Pollitt, Sonia K.; Pallos, Judit; Shao, Jieya; Desai, Urvee A.; Ma, Aye Aye K; Thompson, Leslie Michels; Marsh, J. Lawrence; Diamond, Marc I.

In: Neuron, Vol. 40, No. 4, 13.11.2003, p. 685-694.

Research output: Contribution to journalArticle

Pollitt, SK, Pallos, J, Shao, J, Desai, UA, Ma, AAK, Thompson, LM, Marsh, JL & Diamond, MI 2003, 'A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor', Neuron, vol. 40, no. 4, pp. 685-694. https://doi.org/10.1016/S0896-6273(03)00697-4
Pollitt SK, Pallos J, Shao J, Desai UA, Ma AAK, Thompson LM et al. A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor. Neuron. 2003 Nov 13;40(4):685-694. https://doi.org/10.1016/S0896-6273(03)00697-4
Pollitt, Sonia K. ; Pallos, Judit ; Shao, Jieya ; Desai, Urvee A. ; Ma, Aye Aye K ; Thompson, Leslie Michels ; Marsh, J. Lawrence ; Diamond, Marc I. / A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor. In: Neuron. 2003 ; Vol. 40, No. 4. pp. 685-694.
@article{772e05f7ee82483b8f69b01750e8af37,
title = "A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor",
abstract = "Many neurodegenerative diseases, including tauopathies, Parkinson's disease, amyotrophic lateral sclerosis, and the polyglutamine diseases, are characterized by intracellular aggregation of pathogenic proteins. It is difficult to study modifiers of this process in intact cells in a high-throughput and quantitative manner, although this could facilitate molecular insights into disease pathogenesis. Here we introduce a high-throughput assay to measure intracellular polyglutamine protein aggregation using fluorescence resonance energy transfer (FRET). We screened over 2800 biologically active small molecules for inhibitory activity and have characterized one lead compound in detail. Y-27632, an inhibitor of the Rho-associated kinase p160ROCK, diminished polyglutamine protein aggregation (EC50 ≅ 5 μM) and reduced neurodegeneration in a Drosophila model of polyglutamine disease. This establishes a novel high-throughput approach to study protein misfolding and aggregation associated with neurodegenerative diseases and implicates a signaling pathway of previously unrecognized importance in polyglutamine protein processing.",
author = "Pollitt, {Sonia K.} and Judit Pallos and Jieya Shao and Desai, {Urvee A.} and Ma, {Aye Aye K} and Thompson, {Leslie Michels} and Marsh, {J. Lawrence} and Diamond, {Marc I.}",
year = "2003",
month = "11",
day = "13",
doi = "10.1016/S0896-6273(03)00697-4",
language = "English (US)",
volume = "40",
pages = "685--694",
journal = "Neuron",
issn = "0896-6273",
publisher = "Cell Press",
number = "4",

}

TY - JOUR

T1 - A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor

AU - Pollitt, Sonia K.

AU - Pallos, Judit

AU - Shao, Jieya

AU - Desai, Urvee A.

AU - Ma, Aye Aye K

AU - Thompson, Leslie Michels

AU - Marsh, J. Lawrence

AU - Diamond, Marc I.

PY - 2003/11/13

Y1 - 2003/11/13

N2 - Many neurodegenerative diseases, including tauopathies, Parkinson's disease, amyotrophic lateral sclerosis, and the polyglutamine diseases, are characterized by intracellular aggregation of pathogenic proteins. It is difficult to study modifiers of this process in intact cells in a high-throughput and quantitative manner, although this could facilitate molecular insights into disease pathogenesis. Here we introduce a high-throughput assay to measure intracellular polyglutamine protein aggregation using fluorescence resonance energy transfer (FRET). We screened over 2800 biologically active small molecules for inhibitory activity and have characterized one lead compound in detail. Y-27632, an inhibitor of the Rho-associated kinase p160ROCK, diminished polyglutamine protein aggregation (EC50 ≅ 5 μM) and reduced neurodegeneration in a Drosophila model of polyglutamine disease. This establishes a novel high-throughput approach to study protein misfolding and aggregation associated with neurodegenerative diseases and implicates a signaling pathway of previously unrecognized importance in polyglutamine protein processing.

AB - Many neurodegenerative diseases, including tauopathies, Parkinson's disease, amyotrophic lateral sclerosis, and the polyglutamine diseases, are characterized by intracellular aggregation of pathogenic proteins. It is difficult to study modifiers of this process in intact cells in a high-throughput and quantitative manner, although this could facilitate molecular insights into disease pathogenesis. Here we introduce a high-throughput assay to measure intracellular polyglutamine protein aggregation using fluorescence resonance energy transfer (FRET). We screened over 2800 biologically active small molecules for inhibitory activity and have characterized one lead compound in detail. Y-27632, an inhibitor of the Rho-associated kinase p160ROCK, diminished polyglutamine protein aggregation (EC50 ≅ 5 μM) and reduced neurodegeneration in a Drosophila model of polyglutamine disease. This establishes a novel high-throughput approach to study protein misfolding and aggregation associated with neurodegenerative diseases and implicates a signaling pathway of previously unrecognized importance in polyglutamine protein processing.

UR - http://www.scopus.com/inward/record.url?scp=0242657586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242657586&partnerID=8YFLogxK

U2 - 10.1016/S0896-6273(03)00697-4

DO - 10.1016/S0896-6273(03)00697-4

M3 - Article

C2 - 14622574

AN - SCOPUS:0242657586

VL - 40

SP - 685

EP - 694

JO - Neuron

JF - Neuron

SN - 0896-6273

IS - 4

ER -